NCT03288012

Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Sanquin Research & Blood Bank Divisions · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.

Detailed description

The main objectives of this study are to study the role of the innate and adaptive immune response in allo-antibody formation and furthermore to identify the genetic and time dependent clinical risk factors on alloimmunization in SCD patients. Subjects without allo-antibodies, receiving a red blood cell transfusion, will be included in this study. At 5 time points blood will be drawn from these subjects. (T0: Before transfusion, T1: 1 day after transfusion, T2: 1 week after transfusion, T3: 4 weeks after transfusion, T4: 6 months after transfusion). At each time point specific markers of the immune system will be measured.

Conditions

• Alloimmunization
• Sickle Cell Disease

Timeline

• Start date: 2017-09-20
• Primary completion: 2021-06-01
• Completion: 2021-12-31
• First posted: 2017-09-19
• Last updated: 2019-07-19

Locations

4 sites across 1 country: Netherlands